about
Mucosal immunization in perspective.CpG Oligodeoxynucleotides Facilitate Delivery of Whole Inactivated H9N2 Influenza Virus via Transepithelial Dendrites of Dendritic Cells in Nasal Mucosa.Strategies towards universal pandemic influenza vaccines.Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in miceMucosal vaccines against respiratory syncytial virusIntranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.Fast vaccine design and development based on correlates of protection (COPs).Reducing Campylobacter jejuni colonization of poultry via vaccinationImmunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice.An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with InfectionIntranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.Parents' attitude toward multiple vaccinations at a single visit with alternative delivery methods.Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 virusesInfluenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings.T cell responses to viral infections - opportunities for Peptide vaccination.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Intracellular delivery of HA1 subunit antigen through attenuated Salmonella Gallinarum act as a bivalent vaccine against fowl typhoid and low pathogenic H5N3 virusDry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination.New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.Virus-like particle vaccine by intranasal vaccination elicits protective immunity against respiratory syncytial viral infection in mice.Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.CpG DNA assists the whole inactivated H9N2 influenza virus in crossing the intestinal epithelial barriers via transepithelial uptake of dendritic cell dendrites.A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses.Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity.Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus InfectionsThe application of pseudotypes to influenza pandemic preparednessColonization Limits Efficacy, but Not Immunogenicity, of Live-Attenuated Influenza Virus Vaccine and Enhances Pathogenesis After Influenza Challenge
P2860
Q30368932-71896C73-AA0E-42CE-8101-A522C7A42F13Q30373064-AE666CF4-F028-4925-87AC-0C3D73621FB5Q30382226-AB11751A-94FA-4930-84F4-729682595A91Q30397973-D1B880B5-F7C6-401F-92A9-3B67B3E67F8BQ33604567-AF410B80-6C77-4407-9102-0C37612EA2D0Q33837530-E211D0C0-148F-448C-90AF-1AB3437A36E2Q34070683-61D2E6A6-9BAC-4B04-90CA-E92EBC303041Q34291098-5683E7AD-465F-4B0A-822B-6116A853C9A9Q34633705-8474E9C3-DE4E-4871-B238-2359D58BEE2EQ34650849-0C7ABDD2-E28A-48A6-95AD-4C1F06E4DBFEQ35221169-548B0F0C-164B-4F5F-8EA6-3E65BF552E0AQ36231510-3707DAA8-347D-45BA-8803-84328779DA53Q36239573-1CD0F234-4612-4FC7-9494-5ABCD0D102E2Q36978325-C59109BC-9502-4F8B-AB9C-37249059FA50Q37018558-8511D591-29FF-4528-9432-D98F2A11BAEAQ37338060-1C21BEC8-5967-454E-AC53-99096892DE48Q37718978-911785A3-97C0-470D-9D05-7289EA6D6A45Q38461061-9C9897E5-7545-4F97-B50D-51ABBC8CE073Q38636511-2118FB70-2F0A-42B5-8711-BFDF67960294Q38818697-E286DB2E-B1E2-47ED-8A7A-7D972AACFB2DQ38883770-4EB179A5-9E10-4656-902B-059B71C7424FQ40409972-38600326-3808-4D3C-96BB-6A7C2BC596B7Q42166124-AA752BB5-8A1D-46BD-B81B-32D8466FCE7FQ42177249-C3569B37-848C-475B-8705-FFEA0137C253Q47608146-13833CD6-9C15-48C7-A0C1-7DBFCDAEA747Q50908997-75CA290E-03CA-4B0A-ACF5-82C6236EA360Q57091953-A3D29516-F579-4C56-B7E9-39A0095027E6Q58382401-59D8DE94-0F08-4D28-B9DD-D401E9F7BB9DQ58583885-710E47D2-2C83-44A6-8038-108D4DE183B4
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mucosal immunity and nasal influenza vaccination.
@en
type
label
Mucosal immunity and nasal influenza vaccination.
@en
prefLabel
Mucosal immunity and nasal influenza vaccination.
@en
P2093
P2860
P356
P1476
Mucosal immunity and nasal influenza vaccination.
@en
P2093
Markus A Rose
Stefan Zielen
Ulrich Baumann
P2860
P304
P356
10.1586/ERV.12.31
P577
2012-05-01T00:00:00Z